Finland· FI-REL-REL55977
Synagis
A palivizumab product containing palivizumab, registered in Finland by Orifarm Oy. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Palivizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Palivizumab · ATC J06BD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palivizumab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palivizumab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$51.40
The record
At a glance
Fimea (Finland)- Active substance
- Palivizumab
- Manufacturer
- Orifarm Oy
- Country
- Finland (FI)
- ATC code
- J06BD01
- ATC class
- Palivizumab
- Defined daily dose
- 3.75 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa5354720.5 mlEUR 653.45
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceSYNAGIS 100 mg/ml, solution injectableASTRAZENECA AB
- United StatesSynagisSwedish Orphan Biovitrum AB (publ)
- IrelandSynagis 50 mg/0.5 ml and 100 mg/1 ml Solution for injectionAstraZeneca AB
- NetherlandsSynagis 100 mg/ml, oplossing voor injectieAstraZeneca AB
- United KingdomSynagis 100mg powder and solvent for solution for injection vialsAbbVie Ltd
- BelgiumSynagis 100 mgAstraZeneca
- NorwaySynagisAstraZeneca AB (2)
- SpainSYNAGIS 100 mg POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEAstrazeneca Ab
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/310e2408-decb-48cd-9a6a-cb146562632a GET /v1/drugs/310e2408-decb-48cd-9a6a-cb146562632a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos",
"route": "Lihakseen",
"ddd_unit": null,
"strength": "50 mg / 0.5 ml",
"atc_label": "palivitsumabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/99/117/003",
"fimea_rel_id": "REL55977",
"authorised_at": "2016-01-12"
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.